StockData
Amylyx Pharmaceuticals, Inc. logo

Amylyx Pharmaceuticals, Inc. (AMLX) stock

AMLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$27.52−0.28 (-1.01%)

Close on Nov 17, 2026Market cap $3.07BP/E –Yield –

Amylyx Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Amylyx Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$162.10M. For fiscal 2025 it was -$153.29M. The highest annual figure on record is $38.80M in fiscal 2023.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$153.29M–
FY2024Dec 31, 2024-$314.73M-911.1%
FY2023Dec 31, 2023$38.80M–
FY2022Dec 31, 2022-$201.34M–
FY2021Dec 31, 2021-$82.69M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$45.69M–
Q1 FY2026Mar 31, 2026-$43.78M–
Q4 FY2025Dec 31, 2025-$36.61M–
Q3 FY2025Sep 30, 2025-$36.03M–
Q2 FY2025Jun 30, 2025-$42.86M–
Q1 FY2025Mar 31, 2025-$37.80M–
Q4 FY2024Dec 31, 2024-$40.65M-2202.1%
Q3 FY2024Sep 30, 2024-$75.66M-504.2%
Q2 FY2024Jun 30, 2024-$76.29M-477.6%
Q1 FY2024Mar 31, 2024-$122.13M–
Q4 FY2023Dec 31, 2023$1.93M–
Q3 FY2023Sep 30, 2023$18.72M–
Q2 FY2023Jun 30, 2023$20.20M–
Q1 FY2023Mar 31, 2023-$2.05M–
Q4 FY2022Dec 31, 2022-$44.59M–
Q3 FY2022Sep 30, 2022-$54.68M–
Q2 FY2022Jun 30, 2022-$54.25M–
Q1 FY2022Mar 31, 2022-$47.81M–
Q4 FY2021Dec 31, 2021-$28.32M–
Q3 FY2021Sep 30, 2021-$22.92M–
Q2 FY2021Jun 30, 2021-$18.59M–
Q1 FY2021Mar 31, 2021-$12.87M–

More Amylyx Pharmaceuticals figures

See a number that looks wrong?